RESUMEN
OBJECTIVES: To apply the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to a consecutive series of endometrial cancer (EC) patients diagnosed at a tertiary referral center and assign EC specimens to one of four molecular subgroups using immunohistochemistry (IHC) for p53/mismatch repair protein expression and sequencing for Polymerase Epsilon Exonuclease Domain Mutations (POLE-EDM). Mismatch Repair Deficient (MMR-D) cases were more thoroughly investigated to identify underlying somatic or germline genetic defects. METHODS: Hundred-and eight consecutive endometrial cancer patients, diagnosed between March 2017 and April 2019, were subjected to immunohistochemical and molecular analysis, according to ProMisE. IHC for p53 and the mismatch repair proteins (MLH1, PMS2, MSH6 and PMS2) was performed. All patients were also tested for POLE-EDM by Sanger sequencing. In addition, tumor and corresponding normal tissue of cases with abnormal MMR IHC were tested by PCR for microsatellite instability (MSI) (MSI analysis system, Promega). Hypermethylation of MLH1 promotor was tested with (methylation specific) multiplex ligation dependent probe amplification. MMR-D cases were subjected to germline mutation analysis of the mismatch repair genes, using next generation sequencing on MiSeq (Illumina) with the BRCA Hereditary Cancer MASTR Plus, (Multiplicom/Agilent), RNA mutation analysis and MLPA. RESULTS: FIGO classification was stage IA (n = 54), IB (n = 22) II(n = 8), III(n = 18) and IV(n = 6). Of the 33 patients with MMR-D on IHC (31%), 26 showed MLH1 promotor hypermethylation as the probable cause of MMR-D. The remaining 7 patients without MLH1 promotor hypermethylation were referred for germline analysis of Lynch syndrome. Six patients carried a pathogenic germline mutation in one of the mismatch repair genes: MSH6(n = 3), PMS2(n = 1), MLH1(n = 1) and MSH2 (n = 1). Pathogenic POLE-EDM were identified in 7 (6%) patients. Multiple molecular features (POLE-EDM + MMR-D or POLE-EDM + p53 abnormal) were observed in 4 patients (4%). A high concordance between MMR-D and microsatellite instability was observed in our cohort. In cases of a genetic defect in the MMR genes, we do note a large proportion of cases exhibiting microsatellite instability. On the contrary a hypermutation state, as seen in POLE EDM, does not result in accompanied phenotypic changes in MSI status. CONCLUSION: The ProMisE classification proved to be an efficient and easily implementable system. Future research should elucidate the precise biological and prognostic meaning of the cases with multiple molecular markers.
Asunto(s)
Reparación de la Incompatibilidad de ADN , Enzimas Reparadoras del ADN/genética , Neoplasias Endometriales/clasificación , Anciano , Anciano de 80 o más Años , ADN Polimerasa II/genética , ADN Polimerasa II/metabolismo , Enzimas Reparadoras del ADN/deficiencia , Enzimas Reparadoras del ADN/metabolismo , Neoplasias Endometriales/genética , Neoplasias Endometriales/metabolismo , Neoplasias Endometriales/patología , Femenino , Humanos , Inmunohistoquímica , Inestabilidad de Microsatélites , Persona de Mediana Edad , Homólogo 1 de la Proteína MutL/deficiencia , Homólogo 1 de la Proteína MutL/genética , Homólogo 1 de la Proteína MutL/metabolismo , Estadificación de Neoplasias , Proteínas de Unión a Poli-ADP-Ribosa/genética , Proteínas de Unión a Poli-ADP-Ribosa/metabolismo , Proteína p53 Supresora de Tumor/genéticaRESUMEN
The best known café-au-lait syndrome is neurofibromatosis type 1 (NF1). Legius syndrome (LS) is another, rarer syndrome with café-au-lait macules (CALMs). In young patients their clinical picture is often indistinguishable. We investigated the presence of choroidal abnormalities in syndromes with CALMs as a candidate tool for a more efficient diagnosis. Thirty-four patients with NF1 (14 with a truncating mutation, 14 with a non-truncating mutation and 6 with unknown mutation) and 11 patients with LS. All patients underwent an ophthalmological examination. Infrared images were performed. Choroidal nodules were diagnosed in 65% of the NF1 group. About 71% of NF1 patients with a truncating mutation and 50% of patients with a non-truncating mutation were found to have nodules. Choroidal nodules were seen in 18% of the LS patients, never more than one nodule/eye was detected in this group. Choroidal nodules are more abundantly present in NF1 genotypes with truncating mutations. In contrast, the number of choroidal nodules in LS is comparable with their presence in healthy individuals. Especially at an early age, when the clinical picture is incomplete, the detection of choroidal nodules is of diagnostic value, and helps in an appropriate genetic counselling and follow-up. These results support the suggestion to include choroidal nodules to the diagnostic criteria for NF1.
Asunto(s)
Manchas Café con Leche/diagnóstico , Coroides/fisiopatología , Diagnóstico Diferencial , Neurofibromatosis 1/diagnóstico , Proteínas Adaptadoras Transductoras de Señales , Manchas Café con Leche/genética , Manchas Café con Leche/fisiopatología , Asesoramiento Genético , Humanos , Péptidos y Proteínas de Señalización Intracelular/genética , Proteínas de la Membrana/genética , Neurofibromatosis 1/genética , Neurofibromatosis 1/fisiopatología , Agudeza Visual/genéticaRESUMEN
Introduction: Patients with gastroesophageal adenocarcinoma (GEC) with microsatellite instability-high (MSI-H) or Epstein Barr Virus positivity (EBV+) might be good candidates for immunotherapy. Incidences of about 10% have been reported for both features, but are dependent on geographical region and disease stage. Aim: The aim is to study the prevalence of MSI-H and EBV+ in a Belgian single center cohort of patients with GEC. Methods: We retrospectively assessed the files of all patients with a newly diagnosed GEC between August, 1st 2018 and February, 29th 2020 at the University Hospitals Leuven, Belgium. Microsatellite instability (MSI) status was determined using immunohistochemistry (IHC) and polymerase chain reaction (PCR). EBV+ was assessed using in situ hybridization (ISH). A case report is provided to illustrate the importance of testing for MSI in GEC. Results: 247 gastroesophageal adenocarcinomas were included in this analysis. 62 (56% stage IV) of those were tested for EBV, but only 1 turned out to be EBV positive (1.6%). 116 patients (44.0% stage IV) were tested for MSI, of which 11 were MSI-H (9.5%). Half of the MSI-H tumors identified were at the gastroesophageal junction (GEJ). A patient with MSI-H metastatic GEC obtained a complete response with nivolumab, which persisted after discontinuation of treatment. Conclusion: While we confirm that about 10% of GECs are MSI-H, the incidence of EBV+ in our cohort (1.6%) is clearly lower than expected. Given the important prognostic and predictive implications, every gastroesophageal cancer should be tested for MSI.
Asunto(s)
Infecciones por Virus de Epstein-Barr , Neoplasias Gástricas , Bélgica/epidemiología , Infecciones por Virus de Epstein-Barr/epidemiología , Herpesvirus Humano 4/genética , Humanos , Repeticiones de Microsatélite , Prevalencia , Estudios Retrospectivos , Neoplasias Gástricas/epidemiología , Neoplasias Gástricas/genética , Neoplasias Gástricas/patologíaRESUMEN
BACKGROUND: Neurofibromatosis type 1 (NF1) and Von Hippel-Lindau (VHL) are dominantly inherited late onset cancer predisposition syndromes caused by mutations in the respective tumor suppressor genes (TSGs) NF1 and VHL. Less frequently TSGs are partially or fully deleted. Preimplantation genetic diagnosis (PGD) for cancer predisposition can be applied to select against the mutant allele in carrier couples. However, microdeletions within a single cell can, at present, not be detected by molecular diagnostic methods usually applied for PGD of monogenic disorders. METHODS: We performed PGD using interphase fluorescent in situ hybridization (FISH) on single blastomeres for three couples of which the women carried a microdeletion. One patient had the recurrent 1.4 Mb microdeletion covering NF1, a second suffered from an intragenic NF1 deletion and the last had a deletion of VHL. RESULTS: In total, seven PGD cycles were carried out for these couples, which resulted in the delivery of a healthy twin for the VHL microdeletion carrier. CONCLUSIONS: FISH-based PGD is a straightforward approach to detect (micro)deletions in single blastomeres. It seems likely that the number of conditions for which PGD-FISH is beneficial will increase rapidly with the advent of high-resolution arrays.
Asunto(s)
Hibridación Fluorescente in Situ , Neurofibromatosis 1/diagnóstico , Neurofibromatosis 1/genética , Diagnóstico Preimplantación , Enfermedad de von Hippel-Lindau/diagnóstico , Enfermedad de von Hippel-Lindau/genética , Adulto , Transferencia de Embrión , Femenino , Fertilización In Vitro , Eliminación de Gen , Humanos , Inducción de la Ovulación , Embarazo , Resultado del EmbarazoRESUMEN
The leucine zipper-like transcriptional regulator 1 (LZTR1) protein, an adaptor for cullin 3 (CUL3) ubiquitin ligase complex, is implicated in human disease, yet its mechanism of action remains unknown. We found that Lztr1 haploinsufficiency in mice recapitulates Noonan syndrome phenotypes, whereas LZTR1 loss in Schwann cells drives dedifferentiation and proliferation. By trapping LZTR1 complexes from intact mammalian cells, we identified the guanosine triphosphatase RAS as a substrate for the LZTR1-CUL3 complex. Ubiquitome analysis showed that loss of Lztr1 abrogated Ras ubiquitination at lysine-170. LZTR1-mediated ubiquitination inhibited RAS signaling by attenuating its association with the membrane. Disease-associated LZTR1 mutations disrupted either LZTR1-CUL3 complex formation or its interaction with RAS proteins. RAS regulation by LZTR1-mediated ubiquitination provides an explanation for the role of LZTR1 in human disease.
Asunto(s)
Síndrome de Noonan/genética , Factores de Transcripción/genética , Ubiquitinación/genética , Proteínas ras/metabolismo , Animales , Desdiferenciación Celular , Proliferación Celular , Proteínas Cullin/metabolismo , Modelos Animales de Enfermedad , Femenino , Células HEK293 , Haploinsuficiencia , Células HeLa , Humanos , Masculino , Ratones Mutantes , Mutación , Células de Schwann/citología , Células de Schwann/metabolismoRESUMEN
This corrects the article DOI: 10.1038/srep20010.
RESUMEN
Congenital pseudarthrosis of the tibia (CPT) is a rare disease which normally presents itself during early childhood by anterolateral bowing of the tibia and spontaneous tibial fractures. Although the exact etiology of CPT is highly debated, 40-80% of CPT patients are carriers of a mutation in the Neurofibromatosis Type 1 (NF1) gene, which can potentially result in an altered phenotype of the skeletal cells and impaired bone healing. In this study we use a computational model of bone regeneration to examine the effect of the Nf1 mutation on bone fracture healing by altering the parameter values of eight key factors which describe the aberrant cellular behaviour of Nf1 haploinsufficient and Nf1 bi-allelically inactivated cells. We show that the computational model is able to predict the formation of a hamartoma as well as a wide variety of CPT phenotypes through different combinations of altered parameter values. A sensitivity analysis by "Design of Experiments" identified the impaired endochondral ossification process and increased infiltration of fibroblastic cells as key contributors to the degree of severity of CPT. Hence, the computational model results have added credibility to the experimental hypothesis of a genetic cause (i.e. Nf1 mutation) for CPT.
Asunto(s)
Curación de Fractura/genética , Neurofibromatosis 1/genética , Seudoartrosis/congénito , Tibia/fisiopatología , Regeneración Ósea/genética , Haploinsuficiencia/genética , Humanos , Modelos Teóricos , Osteogénesis/genética , Seudoartrosis/genética , Seudoartrosis/fisiopatología , Seudoartrosis/terapiaRESUMEN
Attempts to develop an ex vivo gene therapy strategy for hemophilia A, using either primary T cells or bone marrow (BM) stem/progenitor cells have been unsuccessful, due to the inability of these cell types to express coagulation factor VIII (FVIII). As an alternative, we evaluated the potential of BM-derived stromal cells which can be readily obtained and expanded in vitro. Human and murine BM stromal cells were transduced with an intron-based Moloney murine leukemia virus (MoMLV) retroviral vector expressing a B-domain-deleted human factor VIII cDNA (designated as MFG-FVIIIdeltaB). Transduction efficiencies were increased 10- to 15-fold by phosphate depletion and centrifugation, which obviated the need for selective enrichment of the transduced BM stromal cells. This resulted in high FVIII expression levels in transduced human (180 +/- 4 ng FVIII/10[6] cells per 24 hr) and mouse (900 +/- 130 ng FVIII/10[6] cells per 24 hr) BM stromal cells. Pseudotyping of the MFG-FVIIIdeltaB retroviral vectors with the gibbon ape leukemia virus envelope (GALV-env) resulted in significantly higher transduction efficiencies (100 +/- 20%) and FVIII expression levels (390 +/- 10 ng FVIII/10[6] cells per 24 hr) in transduced human BM stromal cells than with standard amphotropic vectors. This difference in transduction efficiency correlated with the higher titer of the GALV-env pseudotyped viral vectors and with the higher GALV receptor (GLVR-1) versus amphotropic receptor (GLVR-2) mRNA expression levels in human BM stromal cells. These findings demonstrate the potential of BM stromal cells for gene therapy in general and hemophilia A in particular.
Asunto(s)
Células de la Médula Ósea/metabolismo , Factor VIII/genética , Terapia Genética/métodos , Hemofilia A/terapia , Células del Estroma/metabolismo , Células 3T3 , Animales , Células de la Médula Ósea/citología , Transformación Celular Viral , Células Cultivadas , Expresión Génica , Genes env , Vectores Genéticos , Humanos , Virus de la Leucemia del Gibón , Ratones , Virus de la Leucemia Murina de Moloney , Receptores Virales/genética , Células del Estroma/citologíaRESUMEN
The influence of a test meal on the absorption and disposition of tianeptine (Stablon), a new antidepressant, was investigated in 12 healthy subjects in a two-way, randomized, open cross-over study. Single 12.5-mg oral doses of tianeptine were administered following a night of fasting or immediately after a standardized breakfast. When subjects received tianeptine under fasting conditions the lag time before absorption onset, and the time of the maximum plasma concentration were 0.55 +/- 0.26 hours and 1.29 +/- 0.29 hours, respectively. The maximum plasma concentration was 322 +/- 44 ng/mL, and the total area under the curve 994 +/- 248 ng/hr/mL. When tianeptine was given at the end of the meal, several significant changes were found for tianeptine kinetic parameters; the lag time increased by 0.3 hour and the maximum plasma concentration was lowered (decreased by 25%) and occurred later (tmax increased by 0.5 hour). However, no significant change was found in the area under the plasma concentration-time curve. The trend and extent of changes in the MC5 metabolite parameters were similar to those observed for the parent drug. Absorption of tianeptine is slightly delayed and slowed down without modification of its extent when tianeptine is given at the end of a meal. These slight changes are not clinically relevant for an antidepressant administered three times a day. Despite the changes observed, tianeptine may be given at meal times to improve compliance with treatment.
Asunto(s)
Antidepresivos Tricíclicos/farmacocinética , Alimentos , Tiazepinas/farmacocinética , Adulto , Antidepresivos Tricíclicos/metabolismo , Humanos , Masculino , Distribución Aleatoria , Tiazepinas/metabolismoRESUMEN
In a single-blind trial, 15 obese patients, selected because of their poor response to a weight reducing diet, were treated for 1 month with placebo plus a 1600 calorie diet and then for a further 2 months with a single daily dose of 120 mg fenfluramine plus diet. After the placebo period, the mean weight loss was only 0.89 kg. After the 2-month period on fenfluramine, there was a highly significant (p less than 0.001) additional mean weight loss of 10.18 kg. Biological investigations of the metabolic effects of fenfluramine showed that compared with the placebo period there was an improved glucose tolerance and insulin response after active treatment as well as statistically significant decreases in serum cholesterol (p less than 0.001) and triglycerides (p less than 0.01). During active treatment none of the patients complained of feeling hungry and only a few transient side-effects were reported at the start.
Asunto(s)
Fenfluramina/administración & dosificación , Obesidad/tratamiento farmacológico , Adulto , Anciano , Preparaciones de Acción Retardada , Dieta Reductora , Femenino , Fenfluramina/metabolismo , Fenfluramina/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Obesidad/metabolismoRESUMEN
A study was carried out in patients receiving anticoagulant therapy for various cardiac conditions to evaluate the possible potentiation of their oral anticoagulant medication by benfluorex (450 mg per day) given concomitantly for 9 weeks. Combined treatment was preceded and followed by periods, each of 9 weeks, when the patients received their normal oral coagulant alone. Prothrombin times and weekly tablet consumption of anticoagulant were measured at 3-weekly intervals. Statistical analysis of the results from 22 patients showed that there was no significant difference between prothrombin times and anticoagulant dosage in the period when patients were receiving benfluorex and the values recorded during the baseline and follow-up periods. The results suggest that there was no interaction between benfluorex and the anticoagulant drugs.
Asunto(s)
Anticoagulantes/farmacología , Fenfluramina/análogos & derivados , Administración Oral , Adulto , Anciano , Anticoagulantes/administración & dosificación , Anticoagulantes/uso terapéutico , Interacciones Farmacológicas , Femenino , Fenfluramina/administración & dosificación , Fenfluramina/farmacología , Fenfluramina/uso terapéutico , Cardiopatías/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Tiempo de ProtrombinaRESUMEN
A single-blind crossover study was carried out in 10 subjects with a healthy arterial system to compare the effects of oral piribedil and placebo on the peripheral circulation. Using a telethermographic technique, skin temperature variations from baseline values were measured, at 15 minute intervals over a 2-hour period, after treatment with 3 x 20 mg piribedil tablets, after 1 x 50 mg piribedil in a sustained-release tablet formulation, and after placebo. In contrast to placebo, a vaso-active effect was observed afte piribedil administration on all but 3 occasions. Peak temperature changes appeared later after the sustained-release tablet. Side-effects of treatment were minimal and no significant changes were recorded in blood pressure.
Asunto(s)
Piperazinas/farmacología , Piribedil/farmacología , Temperatura Cutánea/efectos de los fármacos , Administración Oral , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Persona de Mediana Edad , PlacebosRESUMEN
We report three cases with a typical diploid/triploid mixoploidy. Cytogenetic analysis showed a normal diploid karyotype in peripheral blood lymphocytes and a mixture of diploid and triploid cells in skin fibroblasts. We analysed microsatellite markers in patients blood lymphocytes and skin fibroblasts and compared the results with the microsatellite markers in the parents. The extra haploid set was in all three cases of maternal origin. In one case the markers were not very informative but in two cases pericentromeric markers showed a single dose of one paternal allele and a double dose of one maternal allele, more telomeric markers showed one paternal allele and two different maternal alleles. These observations can only be explained by the inclusion of the second polar body in one of the blastomeres at the cleavage stage.
Asunto(s)
Anomalías Múltiples/genética , Blastómeros/ultraestructura , Mosaicismo/genética , Anomalías Musculoesqueléticas/genética , Poliploidía , Análisis Citogenético/métodos , Femenino , Marcadores Genéticos/genética , Humanos , Recién Nacido , Masculino , SíndromeRESUMEN
We report two cases with hemifacial microsomia with body asymmetry associated with mosaic trisomies. The child with mosaic trisomy 9 had skin pigmentary changes. In the boy with mosaic trisomy 22, the extra chromosome 22 originated from a maternal meiosis I error.
Asunto(s)
Aberraciones Cromosómicas , Cromosomas Humanos Par 22 , Cromosomas Humanos Par 9 , Asimetría Facial/genética , Mosaicismo/patología , Humanos , Recién Nacido , Masculino , MeiosisRESUMEN
Twenty-four patients (average age 72 years) took part in a study of the effectiveness and tolerance of indapamide as medication for essential hypertension in elderly subjects. 2.5 mg was administered daily for two months, after which the same amount was given once every other day in order to investigate whether the antihypertensive effect would persist at this dosage. After two months treatment with 1 tablet of indapamide 2.5 mg daily, statistically significant (P less than 0.01) drops in the mean systolic and diastolic blood pressures both erect and supine were observed. In 18 of the patients, the results obtained underwent no statistically significant modifications during the second 2-month treatment period at reduced dosage. In 5 others, dosage had to be maintained at 1 tablet daily. In all cases, the drug was well tolerated clinically. ECG recordings were unchanged. Laboratory results remained within the normal range despite a slight increase in serum uric acid and a slight decrease in potassium.
Asunto(s)
Antihipertensivos/uso terapéutico , Diuréticos/uso terapéutico , Hipertensión/tratamiento farmacológico , Indapamida/uso terapéutico , Anciano , Ensayos Clínicos como Asunto , Femenino , Humanos , Indapamida/administración & dosificación , MasculinoRESUMEN
Neurofibromatosis type 1 is a common autosomal dominant disorder caused by mutations of the NF1 gene on chromosome 17. In only 5%-10% of cases, a microdeletion including the NF1 gene is found. We analyzed a set of polymorphic dinucleotide-repeat markers flanking the microdeletion on chromosome 17 in a group of seven unrelated families with a de novo NF1 microdeletion. Six of seven microdeletions were of maternal origin. The breakpoints of the microdeletions of maternal origin were localized in flanking paralogous sequences, called "NF1-REPs." The single deletion of paternal origin was shorter, and no crossover occurred on the paternal chromosome 17 during transmission. Five of the six cases of maternal origin were informative, and all five showed a crossover, between the flanking markers, after maternal transmission. The observed crossovers flanking the NF1 region suggest that these NF1 microdeletions result from an unequal crossover in maternal meiosis I, mediated by a misalignment of the flanking NF1-REPs.
Asunto(s)
Cromosomas Humanos Par 17/genética , Intercambio Genético/genética , Genes de Neurofibromatosis 1 , Meiosis/genética , Eliminación de Secuencia/genética , Adolescente , Adulto , Niño , Preescolar , Rotura Cromosómica/genética , Femenino , Haplotipos/genética , Humanos , Masculino , Repeticiones de Microsatélite/genética , Linaje , Polimorfismo Genético/genéticaRESUMEN
An NF1 microdeletion is the single most commonly reported mutation in individuals with neurofibromatosis type 1 (NF1). Individuals with an NF1 microdeletion have, as a group, more neurofibromas at a younger age than the group of all individuals with NF1. We report that NF1 microdeletion individuals additionally have a substantially higher lifetime risk for the development of malignant peripheral nerve sheath tumors than individuals with NF1 who do not have an NF1 microdeletion. This should be taken into account in the medical follow-up of individuals with an NF1 microdeletion.
Asunto(s)
Neoplasias de la Vaina del Nervio/genética , Neurofibromatosis 1/genética , Neurofibromina 1/genética , Eliminación de Secuencia/genética , Adolescente , Adulto , Comorbilidad , Humanos , Hibridación Fluorescente in Situ , Persona de Mediana Edad , Neoplasias de la Vaina del Nervio/clasificación , Reacción en Cadena de la Polimerasa , Riesgo , Medición de RiesgoRESUMEN
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder characterized by a marked variability in expression. A more severe phenotype is frequently observed in the group of patients carrying a large NF1 deletion. To study the extent of the microdeletion in these NF1 patients, we generated a partial physical map of the NF1 flanking region. We describe seven PACs and three new polymorphic dinucleotide repeats located outside the NF1 gene and analyzed 20 unrelated individuals with an NF1 microdeletion in a collaborative study. We detected one individual with a substantially smaller deletion including only the NF1 gene and its three embedded genes. In the other 19 patients, the deletion extended at least 1 Mb. The parental origin of the deletion was determined in 15 individuals and was maternal in 13 and paternal in two cases. The new molecular tools described here can be used to unequivocally diagnose a possible extragenic extension of an NF1 deletion.
Asunto(s)
Eliminación de Gen , Genes de Neurofibromatosis 1 , Neurofibromatosis 1/genética , Secuencia de Bases , Cartilla de ADN/genética , Repeticiones de Dinucleótido , Etiquetas de Secuencia Expresada , Femenino , Genes Dominantes , Humanos , Hibridación Fluorescente in Situ , Masculino , Padres , Fenotipo , Mapeo Físico de Cromosoma , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Lugares Marcados de SecuenciaRESUMEN
Neurofibromatosis type 1 (NF1) patients that are heterozygous for an NF1 microdeletion are remarkable for an early age at onset and an excessive burden of dermal neurofibromas. Microdeletions are predominantly maternal in origin and arise by unequal crossover between misaligned NF1REP paralogous sequence blocks which flank the NF1 gene. We mapped and sequenced the breakpoints in several patients and designed primers within each paralog to specifically amplify a 3.4 kb deletion junction fragment. This assay amplified a deletion junction fragment from 25 of the 54 unrelated NF1 microdeletion patients screened. Sequence analysis demonstrated that each of the 25 recombination events occurred in a discrete 2 kb recombination hotspot within each of the flanking NF1REPs. Two recombination events were accompanied by apparent gene conversion. A search for recombination-prone motifs revealed a chi-like sequence; however, it is unknown whether this element stimulates recombination to occur at the hotspot. The deletion-junction assay will facilitate the prospective identification of patients with NF1 microdeletion at this hotspot for genotype-phenotype correlation studies and diagnostic evaluation.